BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29278101)

  • 1. Bayesian hidden Markov models for delineating the pathology of Alzheimer's disease.
    Kang K; Cai J; Song X; Zhu H
    Stat Methods Med Res; 2019 Jul; 28(7):2112-2124. PubMed ID: 29278101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive group lasso with semiparametric hidden Markov models.
    Kang K; Song X; Hu XJ; Zhu H
    Stat Med; 2019 Apr; 38(9):1634-1650. PubMed ID: 30484887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Order selection for heterogeneous semiparametric hidden Markov models.
    Zou Y; Song X; Zhao Q
    Stat Med; 2024 Jun; 43(13):2501-2526. PubMed ID: 38616718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.
    Schuff N; Woerner N; Boreta L; Kornfield T; Shaw LM; Trojanowski JQ; Thompson PM; Jack CR; Weiner MW;
    Brain; 2009 Apr; 132(Pt 4):1067-77. PubMed ID: 19251758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic predictions in Bayesian functional joint models for longitudinal and time-to-event data: An application to Alzheimer's disease.
    Li K; Luo S
    Stat Methods Med Res; 2019 Feb; 28(2):327-342. PubMed ID: 28750578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease progression modeling using Hidden Markov Models.
    Sukkar R; Katz E; Zhang Y; Raunig D; Wyman BT
    Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():2845-8. PubMed ID: 23366517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A joint model for multivariate longitudinal and survival data to discover the conversion to Alzheimer's disease.
    Kang K; Pan D; Song X
    Stat Med; 2022 Jan; 41(2):356-373. PubMed ID: 34726280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.
    Brookmeyer R; Abdalla N
    Clin Trials; 2019 Apr; 16(2):111-119. PubMed ID: 30922116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of Cognitive Impairment Compatible with Early Diagnosis of Alzheimer's Disease. A Bayesian Network Model based on the Analysis of Oral Definitions of Semantic Categories.
    Guerrero JM; Martínez-Tomás R; Rincón M; Peraita H
    Methods Inf Med; 2016; 55(1):42-9. PubMed ID: 25925692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
    Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
    Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
    Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian semi-parametric model for learning biomarker trajectories and changepoints in the preclinical phase of Alzheimer's disease.
    Wang K; Hua W; Wang M; Xu Y
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38775703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease.
    Cheng YW; Chiu MJ; Chen YF; Cheng TW; Lai YM; Chen TF
    Alzheimers Res Ther; 2020 Aug; 12(1):91. PubMed ID: 32753051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
    Mito R; Raffelt D; Dhollander T; Vaughan DN; Tournier JD; Salvado O; Brodtmann A; Rowe CC; Villemagne VL; Connelly A
    Brain; 2018 Mar; 141(3):888-902. PubMed ID: 29309541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.